Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Current Oncology Reports

Volumn 18, Issue 9, 2016, Pages

  Curtis, Susanna A ^a   Cohen, Justine V ^a   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Adoptive cell therapy; Cytokines; Immune checkpoint inhibitors; Immunotherapy; Renal cell carcinoma; Vaccine therapy

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; AFLIBERCEPT; ALPHA INTERFERON; ATEZOLIZUMAB; AVELUMAB; AXITINIB; BEVACIZUMAB; BMS 936559; CYCLOPHOSPHAMIDE; DURVALUMAB; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 2; IPILIMUMAB; ITACITINIB; NIVOLUMAB; PAZOPANIB; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; ROCAPULDENCEL T; SUNITINIB; TG 4010; TICILIMUMAB; TUMOR VACCINE; UNINDEXED DRUG; VARLILUMAB; VITESPEN; VORINOSTAT; CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOW DRUG DOSE; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; ACTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; CARCINOMA, RENAL CELL; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY;

CARCINOMA, RENAL CELL; CELL- AND TISSUE-BASED THERAPY; CYTOKINES; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE;

EID: 84981186468     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-016-0542-9     Document Type: Review

References (78)

1. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
2. Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013;23(1):38–45.
3. Gupta K et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205.
4. Rosenberg SA et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889–97.
5. Escudier B et al. Sequential therapy in renal cell carcinoma. Cancer. 2009;115(10 Suppl):2321–6.
6. Gleave ME et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998;338(18):1265–71.
7. Wierecky J et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66(11):5910–8.
8. Weinstock M, McDermott DF. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. Am Soc Clin Oncol Educ Book, 2015. doi:10.14694/EdBook_AM.2015.35.e291
9. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63(2):128–31.
10. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000;27(2):187–93.
11. Mickisch GH et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.
12. Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.
13. Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42(4):539–48.
14. Rosenberg SA et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907–13.
15. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6 Suppl 1:S55–7.
16. McDermott DF et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(3):561–8.
17. Motzer RJ et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):28–33.
18. Ryan CW et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22):3296–301.
19. Escudier B et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.
20. Rini BI et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.
21. Escudier B et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–50.
22. Rini BI et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.
23. Dandamudi UB et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a cytokine working group (CWG) study. J Immunother. 2013;36(9):490–5.
24. Procopio G et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011;104(8):1256–61.
25. Procopio G et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Annals of Oncology, 2013
26. McDermott DF et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.
27. Rosenberg SA et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92.
28. Rosenberg SA et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85(8):622–32.
29. Tomita Y et al. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol. 1998;5(1):16–21.
30. Wersall P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol. 1995;12(2):69–77.
31. Thompson JA et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989;49(1):235–40.
32. Law TM et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76(5):824–32.
33. Bukowski RM et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. 1991;51(16):4199–205.
34. Kradin R et al. Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2. Transplant Proc. 1988;20(2):336–8.
35. Topalian SL et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6(5):839–53.
36. Dillman R et al. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm. 2004;19(6):730–7.
37. Figlin RA et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17(8):2521–9.
38. Goedegebuure PS et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol. 1995;13(8):1939–49.
39. Thiounn N et al. CD4 TIL (tumor infiltrating lymphocytes) induce complete response in patients treated with IL-2 (interleukin-2). Preliminary study. J Urol (Paris). 1994;100(4):185–8.
40. Liu L et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18(6):1751–9.
41. Engels B et al. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther. 2005;16(7):799–810.
42. Jiang HR et al. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol. 2006;177(7):4288–98.
43. Leisegang M et al. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res. 2010;16(8):2333–43.
44. Amin A et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer. 2015;3:14.
45. Calderhead DM et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother. 2008;31(8):731–41.
46. DeBenedette MA et al. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol. 2008;181(8):5296–305.
47. DeBenedette MA et al. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother. 2011;34(1):45–57.
48. Reinhardt, C., et al., Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). ASCO Meeting Abstracts, 2010. 28(15_suppl): p. 4529.
49. Amato RJ et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010;16(22):5539–47.
50. Harrop R et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother. 2011;60(6):829–37.
51. Oudard S et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother. 2011;60(2):261–71.
52. Jocham D et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363(9409):594–9.
53. May M et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010;59(5):687–95.
54. Wood C et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145–54.
55. Thumar JR, Kluger HM. Ipilimumab: a promising immunotherapy for melanoma. Oncology (Williston Park). 2010;24(14):1280–8.
56. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
57. Cozar JM et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68(8):698–704.
58. Yang JC et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30.
59. Rini BI et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117(4):758–67.
60. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856–64.
61. Brahmer JR et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.
62. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
63. McDermott DF. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20. In treatment refractory advanced stage renal cell carcinoma nivolumab can produce durable responses with a manageable toxicity profile. This response can continue in some patients even after drug treatment is stopped.
64. Motzer RJ et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.
65. Motzer RJ. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. Nivolumab is superior to everolimus in second- or third-line treatment of advanced clear cell renal cell carcinoma. Nivolumab is associated with higher rates of response and improved overall survival while producing fever grade 3 and 4 adverse events.
66. Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
67. McDermott, DF et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016. Atezolizumab, an anti PDL-1 antibody, shows antitumor activity in clear cell and non clear cell advanced renal cell carcinoma with an acceptable toxicity profile. Tumors with both positive and negative PDL-1 expression demonstrate response, though response rate is superior in PDL-1 expressing tumors.
68. Sznol, M et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 33(7_suppl): p. 410.
69. Dudek AZ. Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003. ASCO Meeting Abstracts. 2016;34(2_suppl):559.
70. Wolchok JD et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.
71. Hammers HJ et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2015;33(15_suppl):4516.
72. Hammers HJ. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2014;32(15_suppl):4504.
73. Atkins MB. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): data from the KEYNOTE-029 phase 1 study. ASCO Meeting Abstracts. 2015;33(15_suppl):3009.
74. Choueiri TK. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. ASCO Meeting Abstracts. 2015;33(15_suppl):4500.
75. Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
76. Jilaveanu LB et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 2014;5(3):166–72.
77. Callea M. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. ASCO Meeting Abstracts. 2014;32(15_suppl):4585.
78. Baine MK et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget. 2015;6(28):24990–5002.